Aronora
Share
Reimagining cardio-hematology Our treatments do not have the bleeding side effects of all currently marketed antithrombotics.
Pipeline includes an antibody that selectively reduces the procoagulant activity of the contact coagulation factor XII (F12) and may attenuate consumptive coagulopathy (DIC) that is often associated with life-threatening severe infections including sepsis or RNA viral hemorrhagic fevers associated with Dengue, Marburg, Ebola, Lassa, etc.
12/10/2025
Aronora is proud to share that we presented new data on AB023 and AB062 at hashtag .
AB023 is a first-in-class, Factor XI (FXI) inhibitor designed to bind the Apple 2 (A2) domain of FXI. This differentiated mechanism of action selectively inhibits Factor XII–mediated contact activation of FXI, while preserving thrombin-mediated FXI activation that supports fully functional hemostasis.
AB062 is a first-in-class, antisense oligonucleotide designed to inhibit hepatic production of thrombopoietin – a key regulator of platelet production whose signaling pathway is aberrantly activated in myeloproliferative neoplasms like essential thrombocythemia (ET).
We’re excited to hear KOLs echo our belief in the potential for Aronora's first-in-class programs to better serve patient communities at risk for life-threatening thrombosis.
Thank you to the hashtag organizers for an engaging program and we look forward to a productive year ahead!
Click here to claim your Sponsored Listing.
Category
Contact the practice
Telephone
Website
Address
1818 SW 4th Ave. Suite 102
Portland, OR
97201
Opening Hours
| Monday | 8am - 5pm |
| Tuesday | 8am - 5pm |
| Wednesday | 8am - 5pm |
| Thursday | 8am - 5pm |
| Friday | 8am - 5pm |
| Saturday | 8am - 5pm |
| Sunday | 8am - 5pm |